

tryk over behandlingsmålet. Der er endnu ikke data af tilsvarende validitet fra primærsektoren, idet kun 180 praksis (ca. 10%) er aktivt tilknyttet forløbsordningen (september 2008) og har indrapporteret blodtryk fra ca. 1.400 type 2-diabetespatienter (median 135/80 mmHg).

KORRESPONDANCE: Per Løgstrup Poulsen, Medicinsk Afdeling M, Århus Sygehus, DK-8000 Århus. E-mail: Logstrup@dadlnet.dk

ANTAGET: 15. marts 2009

INTERESSEKONFLIKTER: Ingen

LITTERATUR

1. Bang L, Christensen KL, Hansen KW et al. Diagnostisk blodtryksmåling - på døgnbasis, hjemme og i konsultationen. 2008. www.dahs.dk/fileadmin/BT-maaling_version-17.pdf (1. marts 2009).
2. The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology. 2007 Guidelines for the management of arterial hypertension (ESC). *J Hypertens* 2007;25:1105-87.
3. Kikuya M, Hansen TW, Thijs L et al. Diagnostic thresholds for ambulatory blood pressure monitoring based on 10-year cardiovascular risk. *Circulation* 2007;115: 2145-52.
4. Hansen TW, Kikuya M, Thijs L et al. Prognostic superiority of daytime ambulatory over conventional blood pressure in four populations: a meta-analysis of 7,030 individuals. *J Hypertens* 2007;25:1554-64.
5. de Zeeuw D, Remuzzi G, Parving HH et al. Albuminuria, a therapeutic target for cardiovascular protection in type 2 diabetic patients with nephropathy. *Circulation* 2004;110:921-7.
6. Ibsen H, Olsen MH, Wachtell K et al. Does albuminuria predict cardiovascular outcomes on treatment with losartan versus atenolol in patients with diabetes, hypertension, and left ventricular hypertrophy? The LIFE study. *Diabetes Care* 2006;29:595-600.
7. Sjøllie AK, Klein R, Porta M et al. Effect of candesartan on progression and regression of retinopathy in type 2 diabetes (DIRECT-Protect 2): a randomised placebo-controlled trial. *Lancet* 2008;372:1385-93.
8. Mann JF, Schmieder RE, McQueen M et al. Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial. *Lancet* 2008;372:547-53.
9. Parving HH, Persson F, Lewis JB et al. Aliskiren combined with losartan in type 2 diabetes and nephropathy. *N Engl J Med* 2008;358:2433-46.
10. Kjeldsen SE, Julius S, Mancia G et al. Effects of valsartan compared to amlodipine on preventing type 2 diabetes in high-risk hypertensive patients: the VALUE trial. *J Hypertens* 2006;24:1405-12.
11. Sarafidis PA, Bakris GL. Antihypertensive therapy and the risk of new-onset diabetes. *Diabetes Care* 2006;29:1167-9.
12. Bakris GL, Fonseca V, Katholi RE et al. Metabolic effects of carvedilol vs metoprolol in patients with type 2 diabetes mellitus and hypertension: a randomized controlled trial. *JAMA* 2004;292:2227-36.
13. The DREAM Trial Investigators. Effect of ramipril on the incidence of diabetes. *N Engl J Med* 2006;355:1551-62.

AKADEMISKE AFHANDLINGER



Læge Jakob Møller Hansen:

Familiær hemiplegisk migræne.

En eksperimentel genetisk hovedpinemodel

Ph.d.-afhandling

FORF.S ADRESSE: Tyge Krabbes Vej 6, 1., DK-2300 København S.

E-MAIL: jmh@dadlnet.dk

FORSVARET FINDER STED: den 12. juni, kl. 14.00, Auditorium A, Glostrup Hospital.

BEDØMMERE: professor *Arn M.J.M. van den Maagdenberg*, Holland, professor *Michael Bjørn Russell*, Norge og *John Vissing*.

VEJLEDERE: *Messoud Ashina* og *Jes Olesen*.



Afdelingslæge Lars Hageman Pinborg:

Molecular imaging of receptors and transporters in humans using PET and SPECT: from models to methods and potentials to pitfalls

Disputats

FORF.S ADRESSE: Neurologisk Afdeling, Rigshospitalet, Blegdamsvej 9, DK-2100 København Ø.

E-MAIL: pinborg@nru.dk

FORSVARET FANDT STED: den 4. juni 2009.

OPPONENTER: *Albert Gjedde* og *Ulrik Gether*.



Humanbiolog Louise Vedtofte:

Udvikling og diabetes.

To studier i sandrotter

Ph.d.-afhandling

FORF.S ADRESSE: Afdeling for Udviklingsbiologi, Hagedorn Forskningsinstitut, Niels Steensens Vej 6, DK-2820 Gentofte.

E-MAIL: lvedtofte@hotmail.com

FORSVARET FANDT STED: den 29. maj 2009.

BEDØMMERE: *Jens Juul Holst*, *Jens Damsgaard Mikkelsen* og *Åke Sjöholm*, Sverige.

VEJLEDERE: Dr.scient. *R. Scott Heller* og dr.scient. *Jens Høiriis Nielsen*.